ReviewMedical science monitor : international medical journal of experimental and clinical research2020
An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 1 synthesis or guideline pooled it, 246 citations in OpenAlex.
- A systematic review of SARS-CoV-2 vaccine candidates.Signal transduction and targeted therapy · 2020Pooled it
- Trial
- Acute and chronic kidney injury following COVID-19 infection and vaccination: a narrative review.European journal of translational myology · 2026Article
- Article
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Molecular Dynamics Simulations of the Spike Protein Receptor Binding Domain Adsorption to Material Surfaces.The journal of physical chemistry. B · 2025Article
- Efficacy of Immunostimulatory Adjuvants and Nano-Adjuvants in Current SARS-CoV-2 Vaccines: A Comprehensive Review.Health science reports · 2025Article
- Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.Molecular therapy. Nucleic acids · 2025Review
- Inflammatory and pulmonary function characteristics of bronchial asthma induced by COVID‑19 infection.Biomedical reports · 2025Article
- RNA Through Time: From the Origin of Life to Therapeutic Frontiers in Transcriptomics and Epitranscriptional Medicine.International journal of molecular sciences · 2025Review
- Article
- Targeted-Immunomodulatory Nanomedicines for the Treatment of Autoimmune Diseases via Multiple Administration Routes.International journal of nanomedicine · 2025Review
- Micro-Epigenetic Markers in Viral Genome: SARS-CoV-2 Infection Impact on Host Cell MicroRNA Landscape.Maedica · 2024Article
- Impact of recruitment strategies on individual participation practices in the Canadian National Vaccine Safety Network: prospective cohort study.Frontiers in public health · 2024Article
- Review
- Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.Biomaterials science · 2023Article
- Effect of probiotics as an immune modulator for the management of COVID-19.Archives of microbiology · 2023Article
- An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.International immunopharmacology · 2023Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.